Myriad Genetics Inc (MYGN)

Return on equity (ROE)

Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income US$ in thousands -127,300 -263,300 -112,000 -27,200 -223,700
Total stockholders’ equity US$ in thousands 701,100 783,200 885,800 967,800 881,000
ROE -18.16% -33.62% -12.64% -2.81% -25.39%

December 31, 2024 calculation

ROE = Net income ÷ Total stockholders’ equity
= $-127,300K ÷ $701,100K
= -18.16%

Myriad Genetics Inc's return on equity (ROE) has experienced fluctuations over the years as per the provided data. In December 31, 2020, the ROE was at a significant low of -25.39%, indicating that the company was generating a negative return on shareholders' equity.

By December 31, 2021, there was a slight improvement in ROE, with the percentage improving to -2.81%. However, it still remained negative, albeit to a lesser extent.

In December 31, 2022, the ROE further decreased to -12.64%, indicating a decline in the company's ability to generate profit from its shareholders' equity. This negative trend continued into December 31, 2023, with an ROE of -33.62%, signifying a substantial deterioration in profitability relative to equity.

By December 31, 2024, there was a slight recovery in the ROE to -18.16%, but it remained negative. Overall, Myriad Genetics Inc's ROE trend suggests ongoing challenges in generating satisfactory returns on shareholders' equity, indicating a need for the company to address underlying issues affecting profitability and efficiency.